Table 4.
Cardiovascular outcomes in the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus trial (SAVOR)
| End point | N (%) | Hazard ratio (95% CI) | P value | |
|---|---|---|---|---|
| Saxagliptin (n = 8280) | Placebo (n = 8212) | |||
|
Primary composite end point: CV death, myocardial infarction, or stroke |
613 (7.3) | 609 (7.2) | 1.00 (0.89, 1.12) | 0.99 |
|
Secondary composite end point: CV death, myocardial infarction, stroke, hospitalization for unstable angina, hospitalization for heart failure, or hospitalization for coronary revascularization |
1059 (12.8) | 1034 (12.4) | 1.02 (0.94, 1.11) | 0.66 |
| Individual components of composite end points: | ||||
| Death from any cause | 420 (4.9) | 378 (4.2) | 1.11 (0.96, 1.27) | 0.15 |
| CV death | 269 (3.2) | 260 (2.9) | 1.03 (0.87, 1.22) | 0.72 |
| Myocardial infarction | 265 (3.2) | 278 (3.4) | 0.95 (0.80, 1.12) | 0.52 |
| Ischemic stroke | 157 (1.9) | 141 (1.7) | 1.11 (0.88, 1.39) | 0.38 |
| Hospitalization for unstable angina | 97 (1.2) | 81 (1.0) | 1.19 (0.89, 1.60) | 0.24 |
| Hospitalization for heart failure | 289 (3.5) | 228 (2.8) | 1.27 (1.07, 1.51) | 0.007 |
| Hospitalization for coronary revascularization | 423 (5.2) | 459 (5.6) | 0.91 (0.80, 1.04) | 0.18 |
| Doubling of creatinine level, initiation of dialysis, renal transplantation, or creatinine >6.0 mg/dL | 194 (2.2) | 178 (2.0) | 1.08 (0.88, 1.32) | 0.46 |
| Hospitalization for hypoglycemia | 53 (0.6) | 43 (0.5) | 1.22 (0.82, 1.83) | 0.33 |
Event rates and percentages are 2-year Kaplan–Meier estimates
Adapted with permission from Scirica et al. [46]
CV cardiovascular